Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

XIMLUCI 10 MG/ML SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/XIMLUCI 10 MG/ML SOLUCION INYECTABLE

Approved

STANDARD

XIMLUCI 10 MG/ML SOLUCION INYECTABLE

Stada Arzneimittel Ag🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Nov 22, 2022
Approval ID: 4a2ca03e0e301b7d
Company: Stada Arzneimittel Ag
Type: Standard

Approval Details

Approval Id: 4a2ca03e0e301b7d
Drug Cima Aemps Name: XIMLUCI 10 MG/ML SOLUCION INYECTABLE
Register Number: 1221691001
Holder Company Name: Stada Arzneimittel Ag
Marketing Company Name: Laboratorio Stada S.L.
Holder Company Detail Path: /organization/stada-arzneimittel-ag
Authorization Date: 2022-11-22
Dosage Form: SOLUCIÓN INYECTABLE
Dose: 10 MG/ML
Route Of Administration: VÍA INTRAVÍTREA
Prescription Type: Uso Hospitalario
Commercialized: Yes
Company Name: Stada Arzneimittel Ag
Company Detail Path: /organization/stada-arzneimittel-ag

Company Information

Pharmaceutical Company Name: STADA Arzneimittel AG
Country Name: Germany
Website: http://www.stada.com

Active Ingredients

RANIBIZUMAB

2,3 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Nov 22, 2022

Approval ID

4a2ca03e0e301b7d

Type

Standard

Back to CIMA-AEMPS Approvals